Comprehensive Study Notes: Polycystic Ovary Syndrome (PCOS)
Overview and Etiological Factors of PCOS
Definition & Nomenclature:
- Polycystic Ovary Syndrome (PCOS) is a complex medical condition characterized by a group of symptoms, diverse clinical presentations, and multiple underlying pathophysiological mechanisms.
- Previously referred to as Stein-Leventhal syndrome.
Etiological Factors:
- Genetic Factors: Operates as a complex genetic trait, with key susceptibility loci identified on:
- Chromosome no. 2
- Chromosome no. 9
- Environmental Factors: External environmental exposures contributing to metabolic and endocrine dysfunction.
- Lifestyle Factors: Diet, physical activity, and related behavioral factors.
Primary Pathophysiological Cascades:
- Excessive androgen production
- Defect in folliculogenesis
- Defect in insulin action (Insulin resistance)
- Defect in gonadotropin secretion and action
- Obesity

Hyperandrogenism and Androgen Excess
Anatomical Sources of Androgens:
- Ovaries: Function as the primary and main source of excessive androgen production in PCOS.
- Adrenal Glands: Provide a minor contribution, leading to elevated Dehydroepiandrosterone sulfate () levels.
Circulating Androgen Level Thresholds:
- Normal Females: Serum androgen levels are .
- PCOS Patients: Serum androgen levels range from to .
- Clinical Manifestation: Androgen levels within the to range directly manifest as hirsutism.
Folliculotoxicity of Androgens:
- High local intraovarian androgen concentrations exert a direct toxic effect on developing ovarian follicles.
- Causes complete arrest of follicular growth.
- Prevents maturation of primary and secondary follicles into fully mature Graafian follicles.
Cardiovascular and Metabolic Complications of Androgen Excess:
- Dyslipidemia: Characterized by elevated low-density lipoprotein () and decreased high-density lipoprotein ().
- Increased overall risk of developing coronary heart disease.
Ovarian Manifestations and Ultrasonographic (USG) Findings
- Morphological Characteristics on Ultrasonography:
- Characterized by small, unruptured follicles (pathologically distinct from true ovarian cysts) arranged systematically along the peripheral margin of the ovary.
- Classically described as a "Necklace appearance".

- Quantitative Criteria for Polycystic Ovarian Morphology:
- Rotterdam Criteria:
- Presence of follicles per ovary.
- Follicular size measuring in diameter.
- Total volume of one or both ovaries .
- American and European Societies Criteria:
- Presence of follicles measuring in diameter.
- Clinical Note: Ovaries may appear ultrasonographically normal in a subset of patients with confirmed PCOS.
Dysregulation of Gonadotropins and Ovulatory Dysfunction
Hypothalamic-Pituitary-Ovarian Axis Pathophysiology:
- GnRH Dynamics: Increased pulse frequency of Gonadotropin-Releasing Hormone (GnRH) released from the hypothalamus.
- Pituitary Secretion: High-frequency GnRH pulses selectively drive increased Luteinizing Hormone () secretion by the anterior pituitary gland.
- Ovarian Response: Causes marked theca cell hyperplasia in the ovaries.
LH Dynamics and Altered Gonadotropin Ratios:
- Tonic, persistently elevated LH levels throughout the entire menstrual cycle.
- Complete absence of the mid-cycle LH surge required for follicular rupture.
- FSH : LH Ratio:
- Normal Female Ratio:
- PCOS Ratio: or
- Follicle-Stimulating Hormone (FSH) levels remain strictly normal, while LH levels are significantly increased.
- Optimal Diagnostic Timing: The ideal time window to evaluate serum LH and FSH levels is on Day 2 or Day 3 of the menstrual cycle.
Mechanisms of Anovulation in PCOS:
- Dual underlying mechanisms cause continuous anovulation:
- Direct folliculotoxicity driven by local androgen excess.
- Complete absence of the pre-ovulatory LH surge.
Clinical Manifestations of Ovulatory Dysfunction:
- Infertility due to persistent anovulation.
- Severely decreased progesterone levels () resulting from the total failure of corpus luteum formation.
- Development of secondary () amenorrhea or oligomenorrhea (defined as menstrual cycles per year).
- Increased risk of spontaneous abortions during pregnancy.
Insulin Resistance, Acanthosis Nigricans, and HAIR-AN Syndrome
Pathophysiology of Insulin Resistance in PCOS:
- Insulin resistance occurs independently of patient obesity status:
- Present in of obese PCOS patients.
- Present in of non-obese (thin/lean) PCOS patients.
- Mechanisms leading to hyperandrogenism:
- Drives theca cell hyperplasia in the ovarian stroma.
- Induces overall oversensitivity to LH stimulation due to the loss of the normal physiological ceiling/cut-off mechanism (normally, LH stimulates androgen production from theca cells up to a controlled limit).
- Directly contributes to systemic dyslipidemia.
Acanthosis Nigricans:
- Serves as the primary cutaneous clinical manifestation of systemic insulin resistance.
- Characterized by dark, velvety, hyperpigmented, and thickened skin patches.
- Typical anatomical sites of distribution:
- Nape of the neck
- Axillary region
- Groin folds
- Infra-mammary folds (under breast tissue)
HAIR-AN Syndrome:
- Acronym representing a specific severe subtype of PCOS:
- H / A: Hyper Androgenism
- I / R: Insulin Resistance
- A / N: Acanthosis Nigricans
Applied Diagnostic Protocols for Insulin Resistance:
- Baseline Screening: All patients diagnosed with PCOS must undergo an Oral Glucose Tolerance Test (OGTT) every years.
- Positive Finding: If insulin resistance is detected (), the OGTT must be repeated annually (every year).
Role of Obesity, Estrogen Metabolism, and Menstrual Abnormalities
Prevalence & Pathophysiology of Obesity:
- Present in of PCOS patients.
- Obesity is not a defining diagnostic feature; PCOS can occur in thin/lean individuals.
- Exacerbates systemic metabolic abnormalities by:
- Aggravating insulin resistance.
- Worsening dyslipidemia.
Peripheral Conversion & Estrogen Dynamics:
- Adipose tissue contains high concentrations of the enzyme aromatase.
- Circulating hyperandrogens are converted in peripheral adipocytes by aromatase into estrone (), resulting in marked elevations of estrone ().
- Estradiol to Estrone () Ratio:
- Normal Females:
- Obese PCOS Females:

- Menstrual Presentation by Phenotype:
- Thin PCOS Patient: Most commonly presents with secondary () amenorrhea (maintains normal baseline estrogen levels).
- Obese PCOS Patient: Presents with secondary () amenorrhea or menometrorrhagia (heavy, irregular bleeding caused by unopposed estrone-mediated estrogen breakthrough bleeding).
Comprehensive Hormonal Profile in PCOS
- Summary of Biochemical Biomarkers in PCOS:
| Serum Biomarker | Change in PCOS | Underlying Mechanism / Clinical Notes | | :--- | :--- | :--- | | Testosterone | Increased () | Driven by ovarian theca cell hyper-responsiveness and hyperplasia | | DHEA-S | Increased () | Minor contribution from adrenal hypersecretion | | LDL | Increased () | Component of metabolic dyslipidemia | | AMH (Anti-Müllerian Hormone) | Increased () | Directly proportional to the increased pool of small pre-antral/antral follicles | | Estrone () | Increased () | Elevated specifically in obese PCOS patients due to peripheral adipose aromatization | | LH | Increased () | Driven by increased hypothalamic GnRH pulse frequency | | FSH | Unchanged (Normal) | Pituitary secretion remains baseline | | Estradiol () | Unchanged (Normal) | Baseline secretion maintained without mid-cycle surge | | Prolactin | Unchanged (Normal) | Unaffected baseline levels | | TSH | Unchanged (Normal) | Unaffected baseline thyroid axis | | HDL | Decreased () | Secondary to androgen excess and insulin resistance | | Progesterone | Decreased () | Absence of luteinization and corpus luteum formation due to anovulation | | SHBG (Sex Hormone Binding Globulin) | Decreased () | Synergistically suppressed by hyperandrogenemia and hyperinsulinemia |

Diagnostic Criteria (Rotterdam Criteria) and Differential Diagnosis
Rotterdam Criteria:
- Diagnosis requires the presence of at least 2 out of 3 of the following criteria to establish a provisional diagnosis of PCOS:
- Androgen Excess:
- Biochemically: Hyperandrogenemia (elevated serum testosterone levels).
- Clinically: Hyperandrogenism (hirsutism).
- Ovulatory Dysfunction: Manifesting as secondary () amenorrhea or oligomenorrhea.
- Polycystic Appearance of Ovaries on USG: Presence of follicles measuring in diameter in one or both ovaries, OR an ovarian volume .
Differential Diagnosis — Rule Out Late-Onset Congenital Adrenal Hyperplasia (CAH):
- Following a provisional diagnosis of PCOS, serum levels must be evaluated as a primary screening test:
- Level : Late-onset CAH is definitively ruled out.
- Level : Equivocal result; mandates an ACTH Stimulation Test (the gold-standard diagnostic test):
- Confirms late-onset CAH if positive.
- Rules out late-onset CAH if negative.
- Level : Late-onset CAH is confirmed.
Parameters EXCLUDED from PCOS Diagnostic Criteria:
- The following parameters are clinical/pathophysiological associations but are NOT part of the formal diagnostic criteria for PCOS:
- Obesity
- Altered LH : FSH ratio
- Insulin resistance
- Menometrorrhagia
- "Necklace appearance" on USG
Clinical Complications and Management Considerations
Short-Term Consequences & Complications:
- Menstrual irregularities (oligomenorrhea, secondary amenorrhea, menometrorrhagia)
- Hirsutism
- Alopecia
- Infertility
- Systemic insulin resistance
Long-Term Potential Complications:
- Endometrial Cancer: Significantly heightened risk driven by chronic, unopposed estrogen stimulation ( estrogen / estrone without cyclic progesterone balance).
- Ovarian Cancer: Unclear/variable association ().
- Non-Alcoholic Steatohepatitis (NASH): Secondary to obesity and metabolic syndrome.
- Cardiovascular Disease: Secondary to chronic dyslipidemia (, ) and aggravated insulin resistance.
Standard Diagnostic Workup for PCOS Presenting with Secondary () Amenorrhea:
- Urine Pregnancy Test (UPT): Negative
- Serum LH: Elevated ()
- Serum FSH: Normal